Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersActive in the last 2 years

Anna M E Bruynzeel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7542-8920; OpenAlex author ID A5064280465. Sources: ClinicalTrials.gov.

Their work

Papers
23 (first author 3, last author 3)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
0
Collaborators
78
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 1 trial · 2021: 1 paper, 1 trial · 2022: 2 papers · 2023: 3 papers · 2024: 4 papers, 1 trial · 2025: 4 papers · 2026: 3 papers

Papers 23

  1. The impact of age on quality of life, 90-day mortality, adjuvant chemotherapy, and survival after treatment for localized pancreatic cancer: A nationwide analy… Co-author DOI 10.1016/j.ejca.2026.116822↗
  2. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  3. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  4. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  5. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  6. Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE t… Co-author DOI 10.1136/jitc-2024-010222↗
  7. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  8. Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten. Letter to the Editor regarding: "Pancreat… Co-author DOI 10.1016/j.annonc.2024.05.003↗
  9. Impact of Short-Course Palliative Radiation Therapy on Pancreatic Cancer-Related Pain: Prospective Phase 2 Nonrandomized PAINPANC Trial. Co-author DOI 10.1016/j.ijrobp.2023.08.055↗
  10. MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE… Co-author DOI 10.1016/s2468-1253(24)00017-7↗
  11. Ablative treatments for locally advanced pancreatic cancer: the CROSSFIRE trial: Authors' reply. Co-author DOI 10.1016/s2468-1253(24)00162-6↗
  12. Correction: Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PAN… Last author DOI 10.1186/s12885-023-10521-1↗
  13. Correction: A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation … Co-author DOI 10.1186/s13063-022-07036-8↗
  14. Optimizing patient selection for stereotactic ablative radiotherapy in patients with locally advanced pancreatic cancer after initial chemotherapy - a single c… Last author DOI 10.3389/fonc.2023.1149961↗
  15. Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a na… Last author DOI 10.1186/s12885-022-10419-4↗
  16. A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARC… Co-author DOI 10.1186/s13063-022-06829-1↗
  17. Pancreatic Cancer and Immunotherapy: A Clinical Overview. Co-author DOI 10.3390/cancers13164138↗
  18. Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Co-author DOI 10.1002/cam4.2100↗
  19. The role of biological dose-escalation for pancreatic cancer. Co-author DOI 10.1016/j.ctro.2019.04.020↗
  20. Identification of patients with locally advanced pancreatic cancer benefitting from plan adaptation in MR-guided radiation therapy. First author DOI 10.1016/j.radonc.2018.11.019↗
  21. SBRT for pancreatic cancer: In regard of Bohoudi et al. First author DOI 10.1016/j.radonc.2018.04.024↗
  22. Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer. First author DOI 10.1016/j.radonc.2017.07.028↗
  23. Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced … Co-author DOI 10.1158/1078-0432.ccr-14-3364↗

Trials 3

  1. Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy Principal investigator NCT06272162↗
  2. Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy Principal investigator NCT04881487↗
  3. Stereotactic Radiotherapy vs Best Supportive Care in Unfit Pancreatic Cancer Patients Principal investigator NCT05265663↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 8 shared papers, 1 shared trial, 2021–2026 · strength 1.50
  2. Johanna W. Wilmink · 10 shared papers, 2015–2026 · strength 1.42
  3. Martijn Intven · 5 shared papers, 2 shared trials, 2021–2026 · strength 1.36
  4. Frank J. Lagerwaard · 10 shared papers, 2017–2025 · strength 1.36
  5. Martijn Ruben Meijerink · 9 shared papers, 2015–2025 · strength 1.35
  6. Joost J.M.E. Nuyttens · 6 shared papers, 1 shared trial, 2021–2025 · strength 1.13
  7. Geertjan van Tienhoven · 8 shared papers, 2015–2025 · strength 1.10
  8. Eva Versteijne · 6 shared papers, 2022–2025 · strength 0.99
  9. Izaak Quintus Molenaar · 5 shared papers, 1 shared trial, 2021–2026 · strength 0.98
  10. Bas Groot Koerkamp · 5 shared papers, 1 shared trial, 2021–2025 · strength 0.93
  11. Hjalmar C. van Santvoort · 6 shared papers, 2022–2026 · strength 0.89
  12. Lois A. Daamen · 3 shared papers, 1 shared trial, 2022–2026 · strength 0.86
  13. Hanne D. Heerkens · 3 shared papers, 1 shared trial, 2022–2026 · strength 0.86
  14. Hester J. Scheffer · 4 shared papers, 2021–2025 · strength 0.76
  15. Florentine E. F. Timmer · 4 shared papers, 2021–2025 · strength 0.76
  16. Bart Geboers · 4 shared papers, 2021–2025 · strength 0.76
  17. Hanneke W.M. van Laarhoven · 5 shared papers, 2022–2026 · strength 0.74
  18. Geert Kazemier M · 5 shared papers, 2015–2025 · strength 0.63
  19. Tanja D. de Gruijl · 3 shared papers, 2021–2025 · strength 0.48
  20. Gert J. Meijer · 3 shared papers, 2022–2026 · strength 0.47
  21. Deesje Doppenberg · 3 shared papers, 2022–2023 · strength 0.43
  22. Casper H.J. van Eijck · 3 shared papers, 2022–2025 · strength 0.42
  23. H. M.U. Peulen · 1 shared trial, 2024 · strength 0.39
  24. J. J. Bosch · 1 shared trial, 2024 · strength 0.39
  25. Alette H. Ruarus · 2 shared papers, 2024–2025 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.